How effective is Dolutegravir Sodium in treating HIV (AIDS)?

Dolutegravir Sodium is an integrase inhibitor (Integrase Strand Transfer Inhibitor, INSTI), as part of antiretroviral therapy (ART), are widely used to treat human immunodeficiency virus (HIV) infection, also known as AIDS. Its efficacy has been verified in a number of clinical trials. The following will introduce in detail the efficacy of dolutegravir sodium in the treatment of HIVHIV based on clinical trial data.

1. The FLAMINGOtrial: The FLAMINGO trial is a study comparing dolutegravir sodium with ralpivir /ritonavir, a commonly used combination of antiretroviral drugs. A total of 484 HIV-infected patients participated in the trial, most of whom were inexperienced in treatment. The results of the study showed that at 48 weeks, the viral load suppression effect of the dolutegravir sodium treatment group was better than that of the ralpivir/ritonavir treatment group. 68% of the dolutegravir sodium patients achieved Viral load was below the target of 50 copies/mL and 50% in the ralpivir/ritonavir group.

2. SINGLETrial:The SINGLE trial was designed to evaluate whether dolutegravir sodium combined with two nucleotide reverse transcriptase inhibitors (NRTIs) is more effective than lavidestin pan>/Piledesivir, another commonly used ART combination, compared with the effectiveness of treating untreated HIVinfected people. The study results show that the treatment group of dolutegravir sodium combined with two NRTIs has a more significant effect on suppressing viral load. At 96 weeks, the viral load of patients in this group is lower than 50copies/mL is 80%, while laveidestin/The piledesivir group was 70%.

3. GEMINITrial:GEMINIThe trial is a trial comparing dolutegravir sodium/lamivudine/ A study of treatment with albavirdine, an ART combination of two NRTIs, and darunavir/lamivudine. The study included patients with higher viral loads and limited treatment experience. At 48 weeks, the viral load in the dolutegravir sodium-treated group was less than 50 copies/mL was 89%, while the darunavir /lamivudine group was 88%.

4. TANGOTrial: The TANGO trial is a trial investigating the feasibility and efficacy of dolutegravir sodium in treatment-experienced HIV infected patients. The study results show that the proportion of viral loads in the dolutegravir sodium treatment group below 50 copies/mL is 84%, and the darunavir/lamivudine treatment group was 80%. These data suggest that dolutegravir sodium also has good efficacy in treatment-experienced patients.

Based on the above clinical trial data, dolutegravir sodium has shown significant efficacy in treatingHIV infection. It can effectively reduce viral load, delay disease progression, and improve patients' immune function. Compared with other commonly used ART drugs, dolutegravir sodium has shown higher rates of viral load suppression in some trials, particularly in untreated patients. In addition, the safety and tolerability of dolutegravir sodium have also been confirmed. Common adverse reactions are mostly mild and controllable, such as headache, nausea, etc.

It should be noted that everyone’s situation is different and treatment effects may vary. Before starting to use dolutegravir sodium, patients should consult a professional doctor to fully understand the drug's usage, dosage, side effects and other information to formulate a treatment plan that best suits them.

Dolutegravir sodium has been launched in China, but it has not yet been included in medical insurance. Patients can purchase it in hospital pharmacies at a price of around 1,200 yuan. Please consult the local hospital pharmacy for specific prices. Dolutegravir sodium is cheaper abroad, mainly Indian generic drugs, with a price of around 350 yuan, and the ingredients of domestic original drugs and foreign generic drugs are basically the same.